Post-licensure safety of an adjuvanted hepatitis B vaccine: Final results of the HEPLISAV-B acute myocardial infarction study

Katia Bruxvoort, PhD MPH September 29, 2021

KAISER PERMANENTE SOUTHERN CALIFORNIA





Disclosure/Conflicts of interest

This study was funded by Dynavax Technologies.

Dr. Bruxvoort has also received research support unrelated to this study from Moderna, Pfizer, GlaxoSmithKline, Gilead, and Seqirus.





Background

Heplisav-B[®]

2 doses (0, 1 month)

Novel adjuvant – TLR 9 agonist

Peak seroprotection – 95.4%

Numerical "imbalance" in acute myocardial infarction (AMI) in a single clinical trial

Engerix-B[®]

3 doses (0, 1, 6 months)

Alum adjuvant

Peak seroprotection – 81.3%

No known safety risk








Compare occurrence of AMI in recipients of Heplisav-B and recipients of Engerix-B

Real-world post-licensure safety study Requirement as part of vaccine licensure





Licensure and recommended timeline



Advisory Committee on Immunization Practices (ACIP) recommends new



Study setting







Kaiser Permanente Southern California (KPSC)

- Large, diverse integrated health care system
- 4.7 million members
- 150+ languages
- 15 medical centers (hospitals + 231 medical offices)
- 4.6 million vaccinations administered in 2019

Kaiser Permanente HealthConnect[®]

- Comprehensive electronic health record system
 - Ideal system in place to identify who can benefit from vaccination
- Hep B vaccination alert for patients with diabetes





Study design

Non-randomized cluster design

- Heplisav-B became only available hepatitis B vaccine in family and internal medicine departments at 7 medical centers
- Other 8 medical centers continued to use Engerix-B in family and internal medicine departments
- Selection of medical centers primarily based on operational considerations

Routine vaccine administration over 14 months (Aug 2018 - Oct 2019)

Individuals passively followed through electronic health records for 13 months after first dose during study accrual period (index dose)



Outcome

Primary outcome

- Type 1 AMI (definite + probable)
- First occurrence during 13-month follow-up after index date
 Potential AMI events identified by ICD-10-CM diagnosis codes from inpatient care or emergency department visit with same or next day death
 Events from hospitals outside KPSC captured from claims records
 All events adjudicated by cardiologist reviewers masked to vaccine group
 Results reviewed by independent data monitoring committee



Adjudication process

Cardiologist reviewers used Fourth Universal Definition of Myocardial Infarction to classify potential AMI events as one of the following:

- Definite AMI
- Probable AMI
- Insufficient information
- Not AMI

AMI Type (for definite or probable AMI events)

Cases with disagreement from two cardiologist reviewers went to third reviewer as tiebreaker

Cases with disagreement from all three cardiologist reviewers considered indeterminate



Analysis

Non-inferiority study design

Rule out H_0 : hazard ratio (HR) ≥ 2.0

Cox proportional hazards model with inverse probability of treatment weighting (IPTW)

Covariates considered:

- Socio-demographics
- Diabetes in prior year
- AMI in prior year
- Cardiovascular disease risk factors and medications in prior year
- Comorbidities in prior year
- Healthcare utilization in prior year
- Receipt of concomitant vaccines



Additional analyses

Sensitivity analyses performed using alternative methods:

- Propensity score-adjusted and -stratified Cox proportional hazards model \bullet
- Multivariable Cox proportional hazards regression model \bullet

Additional sensitivity analyses performed for:

- All types of AMI events
- Confirmed type 1 AMI + indeterminate events \bullet





Additional analyses

Subgroup analyses were also performed for individuals with:

- Age <50 years at index dose
- Age ≥50 years at index dose
- Diabetes in the year prior to index dose \bullet
- Hypertension in the year prior to index dose
- Receipt of concomitant vaccination
- Index dose as first hepatitis B vaccination
- Index dose as subsequent hepatitis B vaccination \bullet





Results





Vaccine accrual by dose


	Heplisav-B N (%)	Engerix-B N (%)	Total N (%)	
Recipients with one dose	16,641 (53.4)	20,825 (54.2)	37,466 (53.8)	
Recipients with two doses	14,292 (45.8)	9,951 (25.9)	24,243 (34.8)	
Recipients with three doses	250 (0.8)	7,666 (19.9)	7,916 (11.4)	
Total number of recipients	31,183 (100)	38,442 (100)	69,625 (100)	
*Accrual of index dose from Aug 2018 – Oct 2019; subsequent dose accrued through Nov 2020.				



Standardized differences comparing characteristics for Heplisav-B and Engerix-B recipients before and after inverse probability of treatment weighting (IPTW)

Race/Ethnicity Neighborhood median household income Low-Density Lipoprotein Hemoglobin A1c Diabetes without complications Sex Enrollment duration prior to index dose Cardiac revascularization procedure Hepatits B vaccine in year prior to index dose Antiplatelet agents Metastatic carcinoma Dyslipidemia Dementia History of AMI Peptic ulcer disease Paraplegia and hemiplegia Digoxin Anticoagulants Cerebrovascular disease Antihyperglycemic medication Cancer Connective tissue/rheumatic disease Congestive heart failure Hypertension **HIV/AIDS** Obesity ED visits in year prior to index dose Statin Diabetes with complications Mild liver disease Anti-arrhythmia medication Other lipid lowering medication Nitrate Peripheral vascular disease Insulin Ischemic heart disease Concomitant vaccine same day as index dose Any cardiovascular disease medication Inpatient visits in year prior to index dose Other CVD Moderate or severe liver disease Antihypertension agents Smoking Renal disease Age at index dose, years Depression Chronic pulmonary disease Charlson comorbidity index Outpatient visits in year prior to index dose

> -0.05 -0.10





Standardized Difference



AMI rates

Number of potential events reviewed

Number of type 1 AMI events confirmed

Follow-up time (person-years)

Rate per 1000 person-years

*In Engerix-B group, a higher proportion of events came from claims, and a lower proportion of claims were adjudicated as AMI.


*Background AMI rate among KPSC adults in 2020 is 1.74 per 1000 person-years.

Heplisav-B (N = 31,183)	Engerix-B* (N = 38,442)	Total (N = 69,625)
74	128	202
52 (70.3%)	71 (55.5%)	123 (60.9%)
31,139	38,200	69,339
1.67	1.86	1.77





Cumulative incidence



Comparator: Engerix-B





Results: HR for confirmed type 1 AMI events, Heplisav-B vs. Engerix-B

Cox model with IPTW

Sensitivity analyses

Multivariable-adjusted Cox model*

Propensity score-adjusted Cox model


Propensity score-stratified Cox model

*Adjusted for age, sex, race/ethnicity, history of AMI, Charlson score, hemoglobin A1c, diabetes, renal disease, ischemic heart disease, and nitrate use.

Unadjusted HR (95% CI)	Adjusted HR (95% CI)
0.90 (0.63-1.29)	0.92 (0.63-1.32)
	0.96 (0.67-1.39)
	0.95 (0.66-1.36)
horloop ooro homoglobin 110 d	0.95 (0.66-1.37)



Results: HR for all types of AMI and indeterminate events, Heplisav-B vs. Engerix-B



indeterminate events

Subgroup analysis results: HR for confirmed type 1 AMI events, Heplisav-B vs. Engerix-B

Age <50 years at index dose

Age ≥50 at index dose

Diabetes in the year prior to index dose

Hypertension in the year prior to index dose

Concomitant vaccine recipients

Index dose as first hepatitis B vaccination

Index dose as subsequent hepatitis B vaccinat

*Cox model with IPTW

	Unadjusted HR (95% CI)	Adjusted HR* (95% CI)
	0.89 (0.42-1.88)	0.81 (0.38-1.76)
	0.93 (0.62-1.40)	0.99 (0.65-1.49)
	0.96 (0.65-1.43)	1.00 (0.66-1.50)
	0.83 (0.51-1.33)	0.91 (0.57-1.47)
	0.84 (0.50-1.43)	0.86 (0.51-1.45)
	0.95 (0.64-1.41)	0.98 (0.66-1.46)
ation	0.70 (0.29-1.67)	0.71 (0.29-1.76)





Strengths and limitations

Observational study: Potential for measured and unmeasured confounding

- Considered many sociodemographic and clinical covariates lacksquare
- Conducted multiple sensitivity and subgroup analyses lacksquare

Misclassification of exposure

Vaccine doses were validated

Misclassification of outcome

with lower proportion adjudicated as definite or probable AMI

Generalizability to other patient populations

• Large, diverse population

More events from claims (outside KPSC health system) in Engerix-B group,



Conclusion

Heplisav-B compared to Engerix-B.

There is no evidence of an increased risk of AMI associated with vaccination with





Acknowledgements – KPSC Study Team

Steve Jacobsen Kristi Reynolds Bradley Ackerson William Towner Jeff Slezak Lei Qian Runxin Huang Lina Sy Cheryl Carlson Zendi Solano

Bianca Cheung **Brittany Brown** Chika Okonkwo Claire Park Karen Schenk Katherine Wong Lia Pallivathucal Nidia Golla Sarah Simmons

Contact: Katia.Bruxvoort@uab.edu

KAISER PERMANENTE SOUTHERN CALIFORNIA



